Amunix Pharmaceuticals

Amunix Pharmaceuticals

Biotechnology, 2 Tower Place, South San Francisco, California, 94080, United States, 11-50 Employees

amunix.com

  • instagram
  • LinkedIn

phone no Phone Number: 65********

Who is AMUNIX PHARMACEUTICALS

Amunix is an immuno-oncology company leveraging our proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers (TCEs) and cytoki...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AMUNIX PHARMACEUTICALS

Amunix Pharmaceuticals Org Chart and Mapping

Martina Manack

Executive Assistant to Chief Executive Officer

Employees

Katherine Bock

Vice President Investor Relations & Corporate Communications

Sina Khorsand

Senior Associate Scientist

Javen Liew

Director of Accounting, Assistant Controller

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Amunix Pharmaceuticals

Answer: Amunix Pharmaceuticals's headquarters are located at 2 Tower Place, South San Francisco, California, 94080, United States

Answer: Amunix Pharmaceuticals's phone number is 65********

Answer: Amunix Pharmaceuticals's official website is https://amunix.com

Answer: Amunix Pharmaceuticals's revenue is $50 Million to $100 Million

Answer: Amunix Pharmaceuticals's SIC: 2836

Answer: Amunix Pharmaceuticals's NAICS: 541714

Answer: Amunix Pharmaceuticals has 11-50 employees

Answer: Amunix Pharmaceuticals is in Biotechnology

Answer: Amunix Pharmaceuticals contact info: Phone number: 65******** Website: https://amunix.com

Answer: Amunix is an immuno-oncology company leveraging our proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer. We aim to expand the therapeutic index of TCEs and cytokines, which have demonstrated anti-tumor clinical activity, but have not realized their potential due to dose-limiting on-target, off-tumor toxicity. We address this challenge by using our universal, protease-releasable masking technology (Pro-XTEN), to create next generation, conditionally active TCEs (XPATs) and cytokines (XPACs), that are preferentially activated in tumors as compared to healthy tissues. Experience and culture matter. At Amunix, we challenge ourselves and our colleagues, and bring a critical eye and rigor to everything we do. Biology is complex and hard to predict, but with deep experience, diversity of thinking, and scientific rigor, we believe we maximize our chance of making a real difference for cancer patients.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access